Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II ginisortamab trial in metastatic pancreatic ductal adenocarcinoma
ISRCTN63154609Phase 2Recruiting
- Sponsor
- Cancer Research UK
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, open-label trial of ginisortamab in pancreatic adenocarcinoma (PDAC) (3 arms), sponsored by Cancer Research UK. Primary endpoints: Adverse events related to ginisortamab, Recommended dose of ginisortamab with nab-paclitaxel and gemcitabine and 5 more. Started Jun 2024; status: recruiting.
02
Drugs
ginisortamab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ISRCTN63154609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN63154609.